CAROLINA-full-data

Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta®CAROLINA ® demonstrated no increased cardiovascular risk for Trajenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor Adults with diabetes treated with Trajenta ® experienced significantly fewer events of hypoglycaemia and a modest weight reduction compared to patients treated with glimepiride Detailed results from CAROLINA ® were presented at the American Diabetes Association’s 79th Scientific Sessions 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news